Please wait a minute...

中国生物工程杂志

China Biotechnology
China Biotechnology  2013, Vol. 33 Issue (9): 119-125    DOI:
    
The Types, Safety and Efficacity of the Transplanted Cells
WANG Dian-liang
Department of Pharmacy, The Second Artillery General Hospital, Beijing 100088, China
Download: HTML   PDF(510KB) HTML
Export: BibTeX | EndNote (RIS)      

Abstract  The cells used for cell transplantation therapy mainly consist of hepatocyte, islet cells, dendritic cells, cytokine-induced killer cells, lymphokine activated killer cells, embryonic stem cells, hemopoietic stem cells, and mesenchymal stem cells, etc. Every cell kind has different biological characteristics. Before clinic application, according to the related documents of State Food and Drug Administration, the specific cell agent is studied on its biological characteristics, pharmacology, and toxicology, etc. Animal experiments and clinical tests are carried on to assure its indications and contraindications for assessment of safety and efficacity. After a license has been obtained from State Food and Drug Administration, the related clinical researches and applications can be carried on.

Key wordsCell transplantation therapy      Somatic cell      Stem cell     
Received: 08 July 2013      Published: 25 September 2013
ZTFLH:  R617  
Cite this article:

WANG Dian-liang. The Types, Safety and Efficacity of the Transplanted Cells. China Biotechnology, 2013, 33(9): 119-125.

URL:

https://manu60.magtech.com.cn/biotech/     OR     https://manu60.magtech.com.cn/biotech/Y2013/V33/I9/119

[1] Liau B, Zhang D, Bursac N. Functional cardiac tissue engineering. Regen Med, 2012,7(2):187-206.
[2] Lipinski M J, Biondi-Zoccai G G, Abbate A, et al. Impact of intracoronary cell therapy on left ventricular function in the setting of acute myocardial infarction: A collaborative systematic review and meta-analysis of controlled clinical trials. J Am Coll Cardiol, 2007,50:1761.
[3] Silva E A, Kim E S, Kong H J,et al. Material-based deployment enhances efficacy of endothelial progenitor cells. PNAS, 2008,105:14347-14352.
[4] Li X D, Xu B, Wu J, et al. Review of chinese clinical trials on CIK cell treatment for malignancies. Clin Transl Oncol,2012,14(2):102-108.
[5] Nehls V, Herrmann R, Huhnken M. Guided migration as a novel mechanism of capillary network remodeling is regulated by basic fibroblast growth factor. Histochem Cell Biol,1998,109:319-329.
[6] Simmoneau G, Robbins I M, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol, 2009,54:S43-54.
[7] Lei Z, Yongda L, Jun M, et al. Culture and neural differentiation of rat bone marrow mesenchymal stem cells in vitro. Cell Biol Int, 2007,31:916-923.
[8] Russ H A, Efrat S. Development of human insulin-producing cells for cell therapy of diabetes. Pediatr Endocrinol Rev, 2011,9(2):590-597.
[9] Coopman K. Large-scale compatible methods for the preservation of human embryonic stem cells: current perspectives. Biotechnol Prog, 2011, 27(6):1511-1521.
[10] Meyer G P,Wollert K C, Lotz J, et al. Intracoronary bone marrow cell transfer after myocardial infarction: Eighteen months’follow-up data from the randomized, controlled BOOST (Bone marrow transfer to enhance ST-elevation infarct regeneration)trial. Circulation, 2006,113:1287.
[11] Noce C W, Gomes A, Copello A, et al. Oral involvement of chronic graft-versus-host disease in hematopoietic stem cell transplant recipients. Gen Dent, 2011,59(6):458-462.
[12] Nuri M M, Hafeez S. Autologous bone marrow stem cell transplant in acute myocardial infarction. J Pak Med Assoc. 2012,62(1):2-6.
[13] Patel B B, Majumdar A P. Synergistic role of curcumin with current therapeutics in colorectal cancer: minireview. Nutr. Cancer, 2009,61(6):842-846.
[14] Quevedo H C, Hatzistergos K E, Oskouei B N, et al. Allogeneic mesenchymal stem cells restore cardiac function in chronic ischemic cardiomyopathy via trilineage differentiating capacity. Proc Natl Acad Sci USA, 2009,106:14022-14027.
[15] Schachinger V, Erbs S, Elsasser A, et al. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med,2006,355:1210-1221.
[16] Sekiguchi H, Li M, Losordo D W. The relative potency and safety of endothelial progenitor cells and unselected mononuclear cells for recovery from myocardial infarction and ischemia. J Cell Physiol, 2009,219:235-242.
[17] Kim Y S, Ahn Y. A long road for stem cells to cure sick hearts: update on recent clinical trials. Korean Circ J, 2012,42(2):71-79.
[1] QIAN Yu,DING Xiao-yu,LIU Zhi-qiang,YUAN Zeng-qiang. An Efficient Monoclonal Establishment Method of Genetically Modified Human Pluripotent Stem Cells[J]. China Biotechnology, 2021, 41(8): 33-41.
[2] LI Kai-xiu,SI Wei. Progress in the Treatment of Inflammatory Bowel Diseases by Exosomes Derived from Mesenchymal Stem Cells[J]. China Biotechnology, 2021, 41(7): 66-73.
[3] WANG Yu-xuan,CHEN Ting,ZHANG Yong-liang. Research Progress on the Biological Function of MiR-148[J]. China Biotechnology, 2021, 41(7): 74-80.
[4] ZHAO Jiu-mei,WANG Zhe,LI Xue-ying. Role of Signal Pathways and Related Factors Regulating Cartilage Formation in Bone Differentiation of Bone Marrow Mesenchymal Stem Cells[J]. China Biotechnology, 2021, 41(10): 62-72.
[5] CHEN Fei,WANG Xiao-bing,XU Zeng-hui,QIAN Qi-jun. Molecular Mechanism and Clinical Research Progress of Mesenchymal Stem Cells in the Treatment of Diabetes Mellitus[J]. China Biotechnology, 2020, 40(7): 59-69.
[6] DAI Qi-nan,ZHANG Jing-hong. Advances in Molecular Mechanisms Related to Tumor Multi-drug Resistance, Autophagy, DNA Repair and Tumor Stem Cells[J]. China Biotechnology, 2020, 40(4): 69-77.
[7] YUAN Ya-kun,LIU Guang-yang,LIU Yong-jun,XIE Ya-fang,WU Hao. Comparison of Research and Clinical Transformation on Mesenchymal Stem Cells between China and the US[J]. China Biotechnology, 2020, 40(4): 97-107.
[8] YANG Dan,TIAN Hai-shan,LI Xiao-kun. Research Progress of Fibroblast Growth Factor 5[J]. China Biotechnology, 2020, 40(3): 117-124.
[9] QIU Dan-dan,LU Cai-xia,DAI Jie-jie. Application of Hepatocyte-like Cells Derived from Induced Pluripotent Stem Cells in HCV Infection Model[J]. China Biotechnology, 2020, 40(11): 67-72.
[10] CHEN Li-jun,QU Jing-jing,XIANG Charlie. Therapeutic Potentials, Clinical Studies, and Application Prospects of Mesenchymal Stem Cells in 2019 Novel Coronavirus (COVID-19)[J]. China Biotechnology, 2020, 40(11): 43-55.
[11] ZHU Yongzhao,TAO Jin,REN Meng-meng,XIONG Ran,HE Ya-qin,ZHOU Yu,LU Zhen-hui,DU Yong,YANG Zhi-hong. Autophagy Protects Against Apoptosis of Human Placental Mesenchymal Stem Cells of Fetal Origin Induced by Tumor Necrosis Fator-α[J]. China Biotechnology, 2019, 39(9): 62-67.
[12] Yue-lei FAN,Jiao LU,Da-ming CHEN,Kai-yun MAO. Strategies for Stem Cell Patent Evaluation and Patent Transfer and Transformation[J]. China Biotechnology, 2019, 39(1): 99-106.
[13] Wen-wen SHI,Lei ZHANG. Current Research of Micro Mechanical Environmental Effects on Mesenchymal Stem Cells’ Differentiation[J]. China Biotechnology, 2018, 38(8): 76-83.
[14] Yan ZHENG,Huan YAO,Ke YANG. SFRP5 Inhibites Osteogenic Differentiation of Human Umbilical Cord-derived Mesenchymal Stem Cells Induced by BMP9[J]. China Biotechnology, 2018, 38(7): 7-13.
[15] Ming-ming HAN,Yu-ping LUO. Establishment and Identification of Endogenous CD133 + Cell Tracer Mouse Model[J]. China Biotechnology, 2018, 38(6): 58-62.